Cargando…

Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort

In this study, we aimed to test if the schizophrenia (SCZ) polygenic risk score (PRS) was associated with clinical symptoms in (a) the first episode of psychosis pre-treatment (FEP), (b) at nine weeks after initiation of risperidone treatment (FEP-9W) and (c) with the response to risperidone. We per...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoro, Marcos Leite, Ota, Vanessa, de Jong, Simone, Noto, Cristiano, Spindola, Leticia M., Talarico, Fernanda, Gouvea, Eduardo, Lee, Sang Hyuck, Moretti, Patricia, Curtis, Charles, Patel, Hamel, Newhouse, Stephen, Carvalho, Carolina Muniz, Gadelha, Ary, Cordeiro, Quirino, Bressan, Rodrigo Affonseca, Belangero, Sintia Iole, Breen, Gerome
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119191/
https://www.ncbi.nlm.nih.gov/pubmed/30171181
http://dx.doi.org/10.1038/s41398-018-0230-7
_version_ 1783352039117422592
author Santoro, Marcos Leite
Ota, Vanessa
de Jong, Simone
Noto, Cristiano
Spindola, Leticia M.
Talarico, Fernanda
Gouvea, Eduardo
Lee, Sang Hyuck
Moretti, Patricia
Curtis, Charles
Patel, Hamel
Newhouse, Stephen
Carvalho, Carolina Muniz
Gadelha, Ary
Cordeiro, Quirino
Bressan, Rodrigo Affonseca
Belangero, Sintia Iole
Breen, Gerome
author_facet Santoro, Marcos Leite
Ota, Vanessa
de Jong, Simone
Noto, Cristiano
Spindola, Leticia M.
Talarico, Fernanda
Gouvea, Eduardo
Lee, Sang Hyuck
Moretti, Patricia
Curtis, Charles
Patel, Hamel
Newhouse, Stephen
Carvalho, Carolina Muniz
Gadelha, Ary
Cordeiro, Quirino
Bressan, Rodrigo Affonseca
Belangero, Sintia Iole
Breen, Gerome
author_sort Santoro, Marcos Leite
collection PubMed
description In this study, we aimed to test if the schizophrenia (SCZ) polygenic risk score (PRS) was associated with clinical symptoms in (a) the first episode of psychosis pre-treatment (FEP), (b) at nine weeks after initiation of risperidone treatment (FEP-9W) and (c) with the response to risperidone. We performed a detailed clinical assessment of 60 FEP patients who were antipsychotic-naive and, again, after nine weeks of standardized treatment with risperidone. After blood collection and DNA isolation, the samples were genotyped using the Illumina PsychArrayChip and then imputed. To calculate PRS, we used the latest available GWAS summary statistics from the Psychiatric Genomics Consortium wave-2 SCZ group as a training set. We used Poisson regression to test association between PRS and clinical measurements correcting for the four principal components (genotyping). We considered a p-value < 0.0014 (Bonferroni correction) as significant. First, we verified that the schizophrenia PRS was also able to distinguish cases from controls in this south-eastern Brazilian sample, with a similar variance explained to that seen in Northern European populations. In addition, within-cases analyses, we found that PRS is significantly correlated with baseline (pre-treatment) symptoms, as measured by lower clinical global assessment of functioning (−GAF), higher depressive symptoms and higher scores on a derived excitement factor. After standardized treatment for nine weeks, the correlation with GAF and the excitement factor disappeared while depressive symptoms became negatively associated with PRS. We conclude that drug (and other treatments) may confound attempts to understand the aetiological influence on symptomatology of polygenic risk scores. These results highlight the importance of studying schizophrenia, and other disorders, pre-treatment to understand the relationship between polygenic risk and phenotypic features.
format Online
Article
Text
id pubmed-6119191
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-61191912018-09-04 Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort Santoro, Marcos Leite Ota, Vanessa de Jong, Simone Noto, Cristiano Spindola, Leticia M. Talarico, Fernanda Gouvea, Eduardo Lee, Sang Hyuck Moretti, Patricia Curtis, Charles Patel, Hamel Newhouse, Stephen Carvalho, Carolina Muniz Gadelha, Ary Cordeiro, Quirino Bressan, Rodrigo Affonseca Belangero, Sintia Iole Breen, Gerome Transl Psychiatry Article In this study, we aimed to test if the schizophrenia (SCZ) polygenic risk score (PRS) was associated with clinical symptoms in (a) the first episode of psychosis pre-treatment (FEP), (b) at nine weeks after initiation of risperidone treatment (FEP-9W) and (c) with the response to risperidone. We performed a detailed clinical assessment of 60 FEP patients who were antipsychotic-naive and, again, after nine weeks of standardized treatment with risperidone. After blood collection and DNA isolation, the samples were genotyped using the Illumina PsychArrayChip and then imputed. To calculate PRS, we used the latest available GWAS summary statistics from the Psychiatric Genomics Consortium wave-2 SCZ group as a training set. We used Poisson regression to test association between PRS and clinical measurements correcting for the four principal components (genotyping). We considered a p-value < 0.0014 (Bonferroni correction) as significant. First, we verified that the schizophrenia PRS was also able to distinguish cases from controls in this south-eastern Brazilian sample, with a similar variance explained to that seen in Northern European populations. In addition, within-cases analyses, we found that PRS is significantly correlated with baseline (pre-treatment) symptoms, as measured by lower clinical global assessment of functioning (−GAF), higher depressive symptoms and higher scores on a derived excitement factor. After standardized treatment for nine weeks, the correlation with GAF and the excitement factor disappeared while depressive symptoms became negatively associated with PRS. We conclude that drug (and other treatments) may confound attempts to understand the aetiological influence on symptomatology of polygenic risk scores. These results highlight the importance of studying schizophrenia, and other disorders, pre-treatment to understand the relationship between polygenic risk and phenotypic features. Nature Publishing Group UK 2018-08-31 /pmc/articles/PMC6119191/ /pubmed/30171181 http://dx.doi.org/10.1038/s41398-018-0230-7 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Santoro, Marcos Leite
Ota, Vanessa
de Jong, Simone
Noto, Cristiano
Spindola, Leticia M.
Talarico, Fernanda
Gouvea, Eduardo
Lee, Sang Hyuck
Moretti, Patricia
Curtis, Charles
Patel, Hamel
Newhouse, Stephen
Carvalho, Carolina Muniz
Gadelha, Ary
Cordeiro, Quirino
Bressan, Rodrigo Affonseca
Belangero, Sintia Iole
Breen, Gerome
Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
title Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
title_full Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
title_fullStr Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
title_full_unstemmed Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
title_short Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
title_sort polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119191/
https://www.ncbi.nlm.nih.gov/pubmed/30171181
http://dx.doi.org/10.1038/s41398-018-0230-7
work_keys_str_mv AT santoromarcosleite polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT otavanessa polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT dejongsimone polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT notocristiano polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT spindolaleticiam polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT talaricofernanda polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT gouveaeduardo polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT leesanghyuck polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT morettipatricia polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT curtischarles polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT patelhamel polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT newhousestephen polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT carvalhocarolinamuniz polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT gadelhaary polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT cordeiroquirino polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT bressanrodrigoaffonseca polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT belangerosintiaiole polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort
AT breengerome polygenicriskscoreanalysesofsymptomsandtreatmentresponseinanantipsychoticnaivefirstepisodeofpsychosiscohort